The efficacy of cancer immunotherapies can vary among patients, with a range of factors influencing treatment effect. One of these factors is T cell fitness.
Innovation is not a destination; it is a journey defined by curiosity, courage, and a relentless commitment to learning.
As we celebrate medical and scientific advances, we must also recognize the challenges in how we evaluate and deliver new treatments.
With the rise of immunotherapies for cancer, the limitations of RECIST-based evaluation are becoming more important.
You are about to leave Immunocore’s website and will be redirected to an external site. Immunocore is not responsible for the accuracy, security, or privacy policy of third-party platforms.
